Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review
Lei Miao, Jing Xu, Giovanni Targher, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 725-738
Open Access | Times Cited: 19

Showing 19 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 199
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 7, pp. 802-811
Closed Access | Times Cited: 8
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, J Thymis, Stamatios Lampsas, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 428-428
Open Access | Times Cited: 1
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome
David S.H. Bell, Terri Jerkins
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 11, pp. 3093-3102
Closed Access | Times Cited: 18
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease
Iqra Mazhar, Mohamed Yasir, Saba Sarfraz, et al.
Cureus (2023)
Open Access | Times Cited: 13
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Exploring the Mechanism of Action of GLP-1RAs in the Treatment of Non-Alcoholic Fatty Liver Disease Combined with Diabetes Based on Network Pharmacology
高林 齐
Medical Diagnosis (2025) Vol. 15, Iss. 02, pp. 200-210
Closed Access
AI‐based digital pathology provides newer insights into lifestyle intervention‐induced fibrosis regression in MASLD: An exploratory study
Hai‐Yang Yuan, Xiaofei Tong, Yayun Ren, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2572-2582
Closed Access | Times Cited: 3
Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury
Hewei Wei, Ting Zhao, Xinglong Liu, et al.
Molecules (2024) Vol. 29, Iss. 15, pp. 3537-3537
Open Access | Times Cited: 3
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
Tzu-I Chen, Fu‐Jen Lee, Wan‐Lun Hsu, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1148-1148
Open Access | Times Cited: 7
Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Portal hypertension & cirrhosis (2022) Vol. 1, Iss. 1, pp. 57-65
Open Access | Times Cited: 11
The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy
Bo Yuan, Jichun Ma, Jing Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 8
Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials
Hao Wang, Qianqian Ma, Youpeng Chen, et al.
Obesity Reviews (2024) Vol. 25, Iss. 6
Open Access | Times Cited: 1
Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research
Elena V. Biryukova
Meditsinskiy sovet = Medical Council (2024), Iss. 6, pp. 72-80
Open Access | Times Cited: 1
Metabolic dysfunction-associated fatty liver disease: bridging cardiology and hepatology
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Cardiology Plus (2024)
Open Access | Times Cited: 1
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 377-380
Open Access | Times Cited: 2
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 2
Protective Effects of Plum on Liver and Gut Injury in Metabolic Dysfunction-Associated Fatty Liver Disease
Ji-Su Kim, Sun Mee Hong, Do‐Kyun Kim, et al.
Nutrients (2024) Vol. 16, Iss. 21, pp. 3760-3760
Open Access


Diabetes Obesity Metabolic Syndrome (2023), Iss. 5
Open Access
Page 1

Scroll to top